With 1.02 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.83 million shares. During the session, the Healthcare Plans company that operates in wider Healthcare sector, reached to the highest price of $243.43 whereas the lowest price it dropped to was $238.33. The 52-week range on HUM shows that it touched its highest point at $406.46 and its lowest point at $212.45 during that stretch. It currently has a 1-year price target of $287.09. With its current market cap of 28.95 billion, HUM has annualized dividend of $3.54 while the current yield stands at 1.48%. HUM paid its most recent dividend on 1743120000, while the ex-dividend date for that was 1750982400. Beta for the stock currently stands at 0.44.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of HUM was down-trending over the past week, with a drop of -1.44%, but this was up by 5.86% over a month. Three-month performance dropped to -11.31% while six-month performance fell -2.91%. The stock lost -5.44% in the past year, while it has lost -33.00% so far this year. A look at the trailing 12-month EPS for HUM yields 14.14 with Next year EPS estimates of 14.47. For the next quarter, that number is 5.90. This implies an EPS growth rate of 0.87% for this year and -11.53% for next year. EPS is expected to grow by 10.78% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -13.05%.
Float and Shares Shorts:
At present, 120.69 million HUM shares are outstanding with a float of 120.42 million shares on hand for trading. On 2025-06-13, short shares totaled 4.25 million, which was 353.0 higher than short shares on 1747267200. In addition to Mr. James A. Rechtin M.B.A. as the firm’s President, CEO & Director, Mr. Bruce Dale Broussard serves as its Strategic Advisor.
Institutional Ownership:
Through their ownership of 0.96119004 of HUM’s outstanding shares, institutional investors have minority control over the company.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for HUM since 18 analysts follow the stock currently. There are 11 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 7 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With HUM analysts setting a high price target of 402.23 and a low target of 244.0, the average target price over the next 12 months is 294.92303. Based on these targets, HUM could surge 67.67% to reach the target high and rise by 1.71% to reach the target low. Reaching the average price target will result in a growth of 22.94% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of $16.26077 being high and $15.86051 being low. For HUM, this leads to a yearly average estimate of $16.12068.
